Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Celea Therapeutics dosed its first patient in the Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis. This is a positive clinical development milestone, supporting advancement of the program into late-stage testing.

Analysis

Celea Therapeutics dosed its first patient in the Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis. This is a positive clinical development milestone, supporting advancement of the program into late-stage testing.